Physician profile
Robert Feferman
NPI 1154479210
$7,397.14
in general payments reported to CMS, 2019-2025
48 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $776 · 2021: $747 · 2022: $1,695 · 2023: $1,399 · 2024: $1,067 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,507 · Gift: $12.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,506.99 |
| Gift | $12.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,826.38 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,437.71 | 2019-2025 | |
| Ascend Therapeutics US, LLC | $502.89 | 2022-2024 | |
| Lilly USA, LLC | $371.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $304.45 | 2022-2023 | Fanapt, Hetlioz |
| Ibsa Pharma INC. | $289.40 | 2019-2025 | Tirosint, Licart, Tirosint |
| Vertical Pharmaceuticals, LLC | $180.16 | 2019-2020 | |
| Amgen INC. | $174.07 | 2023-2025 | Evenity, Tepezza |
| Amneal Pharmaceuticals LLC | $167.69 | 2019-2025 | Unithroid |
| Corcept Therapeutics | $162.31 | 2019-2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $155.69 | 2022-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $150.44 | 2023-2025 | Sunosi, Symbravo |
| Abbott Laboratories | $125.17 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $120.06 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.19 | 2022-2024 | Xifaxan |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Feferman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.